BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Thursday.

A number of other equities research analysts also recently weighed in on the company. Zacks Investment Research raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a report on Tuesday, April 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 12th. Noble Financial reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Sunday, May 28th. HC Wainwright reaffirmed a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Tuesday. Finally, BidaskClub raised BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $8.00.

BioCryst Pharmaceuticals (NASDAQ BCRX) opened at 4.51 on Thursday. BioCryst Pharmaceuticals has a 12 month low of $3.73 and a 12 month high of $9.25. The firm has a 50-day moving average price of $5.45 and a 200 day moving average price of $6.31. The company’s market cap is $362.69 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.02. The business had revenue of $3.10 million during the quarter, compared to analyst estimates of $5.79 million. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 320.73%. The company’s revenue for the quarter was down 35.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.22) EPS. On average, equities analysts expect that BioCryst Pharmaceuticals will post ($0.72) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/10/biocryst-pharmaceuticals-inc-bcrx-lowered-to-sell-at-valuengine.html.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after buying an additional 45 shares during the last quarter. Legal & General Group Plc boosted its position in shares of BioCryst Pharmaceuticals by 4.9% in the second quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after buying an additional 860 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of BioCryst Pharmaceuticals during the second quarter worth approximately $126,000. Bank of America Corp DE boosted its position in shares of BioCryst Pharmaceuticals by 43.3% in the first quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock worth $210,000 after buying an additional 7,568 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in shares of BioCryst Pharmaceuticals by 4.7% in the second quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock worth $185,000 after buying an additional 1,500 shares during the last quarter. Institutional investors own 84.49% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.